Black Friday: 25% off your first payment on everything.
Shop now
Take Home Points

Rapamycin inhibits mTOR, the master regulator of cellular growth, triggering autophagy and cellular maintenance programs central to both disease treatment and aging biology.

FDA-approved applications span organ transplantation, oncology (breast cancer, renal cell carcinoma), rare genetic diseases (TSC, LAM), and coronary stent coating — rapamycin is already one of medicine's most versatile drugs.

In mice, rapamycin extends median lifespan by up to 26% even when started in mid-to-late life — the first drug ever to do so in a mammalian model.

Low-dose rapamycin rejuvenated vaccine responses in elderly humans in a randomized trial, providing the strongest direct evidence that it can modify aging biology in people, not just rodents.

Intermittent, weekly dosing is not a shortcut — it is a precision pharmacological strategy designed to capture mTORC1 benefits while allowing metabolic recovery between doses.

Topical rapamycin reduces skin senescence markers in clinical studies, offering a path to tissue-specific effects without systemic immunosuppression.

Clinical supervision is non-negotiable: lipid panels, blood counts, and ongoing monitoring are what separate a protocol from a gamble.

In 1972, a soil sample from Easter Island — known to the Rapa Nui people as Rapa Nui, from which the drug takes its name — yielded a bacterium called Streptomyces hygroscopicus. The compound it produced, rapamycin, turned out to be one of the most biologically consequential molecules ever discovered. Fifty years later, the question of what rapamycin is used for has expanded far beyond its original application as an antifungal agent, through organ transplantation, oncology, and rare genetic disease, into the vanguard of longevity science. Few molecules have made that journey.

At its core, rapamycin works by inhibiting a protein called mTOR, short for mechanistic target of rapamycin. mTOR functions as a master regulator of cellular growth and metabolism, integrating signals from nutrients, energy status, and growth factors to decide whether a cell should grow, divide, or conserve resources. When rapamycin binds to mTOR, it tips that decision toward conservation, triggering a suite of cellular maintenance processes that have profound implications for both disease and aging. Understanding what rapamycin does at this molecular level is the key to understanding every clinical application that follows.

Rapamycin does not simply suppress the immune system or slow a tumor — it reprograms how cells interpret abundance and scarcity, a distinction that explains its remarkable breadth of biological effects.

The mTOR Axis: A Molecular Crossroads

To appreciate rapamycin's clinical range, it helps to understand mTOR not as a single protein but as the hub of two distinct molecular complexes: mTORC1 and mTORC2. Think of mTORC1 as the accelerator pedal of cellular growth. When nutrients are plentiful, mTORC1 is active, promoting protein synthesis, cell division, and the suppression of autophagy, the process by which cells break down and recycle their own damaged components. mTORC2, by contrast, governs cell survival, cytoskeletal organization, and glucose metabolism. Rapamycin acutely inhibits mTORC1 and, with chronic exposure, can partially inhibit mTORC2 as well [1].

The evolutionary logic of mTOR is elegant: in an environment of scarce food, suppressing growth and ramping up cellular recycling is a survival strategy. Rapamycin essentially mimics that signal pharmacologically. When mTORC1 is inhibited, cells activate autophagy, clearing out misfolded proteins, dysfunctional mitochondria, and other cellular debris that accumulates with age. This is not an obscure side effect. It is likely one of the primary mechanisms through which rapamycin extends lifespan in model organisms, and it underlies nearly every longevity-focused application being studied today [2].

The two mTOR complexes also explain the therapeutic trade-offs that clinicians must navigate. Acute mTORC1 inhibition drives the benefits most associated with longevity and immune regulation. Chronic, high-dose inhibition that bleeds into mTORC2 suppression is associated with insulin resistance and metabolic side effects. This distinction between dose and schedule is not academic. It is the central variable that separates rapamycin's transplant-era toxicity profile from the intermittent, low-dose protocols being explored for healthy aging [3].

Organ Transplantation: The Original Indication

Rapamycin entered clinical medicine through transplantation, approved by the FDA in 1999 under the brand name Sirolimus for the prevention of kidney transplant rejection. The immune system's job is to destroy anything it recognizes as foreign, and a transplanted organ is precisely that. Calcineurin inhibitors like cyclosporine and tacrolimus, the earlier immunosuppressants, blocked T-cell activation at one point in the signaling cascade. Rapamycin worked at a completely different step, blocking the proliferative response of already-activated T cells by inhibiting mTORC1-driven cell division [4].

This complementary mechanism made rapamycin a valuable addition to combination immunosuppressive regimens. The CONVERT trial and subsequent studies demonstrated that sirolimus-based protocols could preserve kidney function and reduce the incidence of certain post-transplant cancers compared to calcineurin inhibitor-based regimens, though with their own side effect profile including impaired wound healing, hyperlipidemia, and mouth sores [5]. The transplant experience gave clinicians decades of pharmacokinetic data on rapamycin and established the safety thresholds that later researchers would use as reference points when designing longevity protocols.

Beyond kidney transplants, rapamycin-class drugs have been used in heart and liver transplantation, particularly in patients who develop calcineurin inhibitor nephrotoxicity. The clinical message from transplantation is clear: at the doses required to continuously suppress the immune system, rapamycin carries meaningful risks. That observation, paradoxically, helped longevity researchers ask a sharper question: what happens at much lower doses, given intermittently?

Oncology: When mTOR Drives Cancer

The same growth-promoting function that makes mTOR a target in transplant immunosuppression also makes it a compelling target in cancer. Many tumors carry mutations that constitutively activate the PI3K-AKT-mTOR signaling pathway, essentially locking the cellular accelerator in the "on" position. Rapamycin analogs, called rapalogs, have been developed specifically for oncology, with more favorable pharmaceutical properties than rapamycin itself [6].

Everolimus, the most widely used rapalog in oncology, has regulatory approval for hormone receptor-positive breast cancer in combination with exemestane, advanced renal cell carcinoma, pancreatic neuroendocrine tumors, and certain rare cancers. Temsirolimus holds approval for renal cell carcinoma. These are not marginal approvals. The BOLERO-2 trial, which led to the breast cancer indication for everolimus, showed a doubling of progression-free survival when everolimus was added to hormonal therapy in patients who had progressed on aromatase inhibitors, a clinically meaningful result in a treatment-resistant population [7].

The oncology applications illuminate an important nuance: rapalogs are cytostatic rather than cytotoxic. They do not directly kill cancer cells. They suppress their proliferation. This means they are most effective as part of combination strategies, and resistance can develop as cancer cells find alternative routes around mTOR inhibition, often through feedback activation of AKT. Second-generation dual mTORC1/mTORC2 inhibitors and combinations with PI3K inhibitors are under active investigation to address this [8].

Rapalogs do not kill cancer cells. They stop them from dividing, a distinction that explains both their clinical utility and their limitations as monotherapy.

Rare Diseases: Tuberous Sclerosis Complex and LAM

Some of rapamycin's most dramatic effects have been in rare diseases where mTOR hyperactivation is caused by specific genetic mutations. Tuberous sclerosis complex, or TSC, is a genetic disorder caused by loss-of-function mutations in either the TSC1 or TSC2 gene, proteins that normally act as brakes on mTORC1. Without these brakes, mTOR runs continuously, producing benign tumors in the brain, kidneys, lungs, skin, and heart. These are not metaphorical tumors. They cause seizures, kidney failure, and cognitive impairment in children and adults [9].

Everolimus has demonstrated substantial efficacy in reducing tumor volume and seizure frequency in TSC patients, with the EXIST-1 and EXIST-2 trials showing reductions in brain lesion volume and kidney angiomyolipoma size that were previously unachievable with any therapy [10]. These results represent one of the clearest possible demonstrations of what happens when you correctly identify and pharmacologically target the precise molecular defect driving a disease.

Lymphangioleiomyomatosis, or LAM, is a rare progressive lung disease that almost exclusively affects women of childbearing age. Like TSC, it involves mTOR hyperactivation, in this case driving the abnormal proliferation of smooth-muscle-like cells in the lungs. The MILES trial showed that sirolimus stabilized lung function and improved quality of life in LAM patients, leading to FDA approval of sirolimus for LAM in 2015 [11]. For a disease with no other disease-modifying treatment, this was transformative.

The Longevity Discovery: Extending Life in Mice

The pivot toward longevity science began with a landmark 2009 paper from the National Institute on Aging's Interventions Testing Program. Rapamycin was fed to genetically heterogeneous mice starting at 600 days of age, the equivalent of roughly 60 human years. Despite this late start, male mice lived 9% longer and female mice 14% longer than controls. It was the first time any drug had extended lifespan in mammals when started in mid-to-late life [12].

Subsequent ITP studies reinforced the finding. At higher doses, rapamycin extended median lifespan in mice by as much as 23-26% in both sexes, with improvements in multiple age-related conditions including cancer incidence, cardiac function, and cognitive performance [13]. Crucially, mice on rapamycin did not simply live longer in a diminished state. They maintained healthier function longer, shifting the compression of morbidity toward the end of the lifespan. This distinction between lifespan and healthspan matters enormously for how clinicians think about these findings.

The mechanisms behind these effects converge on several pathways. Autophagy induction clears the proteotoxic debris, misfolded protein aggregates and dysfunctional organelles, that accumulates with age and drives many age-related pathologies. Reduction in cellular senescence, the state in which cells stop dividing but refuse to die and instead secrete inflammatory signals, appears to be another contributor. And attenuation of mTORC1 activity in immune cells preserves immune function in a way that mirrors the rejuvenating effects seen in some human studies [14].

Mice fed rapamycin starting at the equivalent of 60 human years still lived significantly longer than controls — suggesting that the aging process remains modifiable even in mid-to-late life.

Rapamycin and the Aging Immune System

One of the most compelling human studies to date came not from a longevity trial but from a vaccine study. Researchers at Novartis tested a low-dose rapalog, RAD001 (everolimus), in elderly volunteers over six weeks prior to influenza vaccination. Those who received the drug showed enhanced antibody responses to the vaccine and a reduction in the percentage of exhausted T cells compared to placebo recipients [15].

This finding addresses one of the most clinically important consequences of aging: immunosenescence, the gradual decline in immune function that makes older adults more susceptible to infection, less responsive to vaccines, and more prone to cancer that escapes immune surveillance. The prevailing assumption was that an immunosuppressant could only worsen this. The study suggested the opposite: at low doses, rapamycin appeared to rejuvenate aspects of aged immune function rather than suppress them. The likely explanation is that it clears exhausted, dysfunctional immune cells through autophagy while allowing the remaining cells to function better [15].

A follow-up study by the same group confirmed and extended these findings, showing that RAD001 reduced the proportion of PD-1-positive T cells, a marker of immune exhaustion, in elderly subjects, with effects lasting after drug discontinuation [16]. This work is among the strongest direct evidence that rapamycin-class drugs can modulate aging biology in humans, not just rodents. It has become a foundational reference point for every physician considering rapamycin in a longevity context.

Cardiovascular Effects: Stents, Plaques, and Cardiac Aging

Rapamycin entered cardiology through an unexpected route. Drug-eluting coronary stents coated with sirolimus or its analogs became the standard of care for coronary artery disease interventions in the mid-2000s. The drug's anti-proliferative effect on smooth muscle cells prevented the in-stent restenosis, the re-narrowing from scar tissue overgrowth, that plagued bare-metal stents. Sirolimus-eluting stents reduced restenosis rates from roughly 30% to under 10% [17]. This is one of rapamycin's most established and widespread clinical applications, deployed in millions of patients worldwide.

Beyond stents, rapamycin's effects on cardiac aging are attracting serious research attention. The heart accumulates senescent cells and dysfunctional mitochondria with age, contributing to diastolic dysfunction and reduced cardiac reserve. Studies in aged mice have shown that rapamycin treatment improves cardiac function, reduces senescent cell burden in the myocardium, and partially reverses age-related changes in cardiac gene expression [18]. These are animal data, and translating them to humans requires caution. But the mechanistic rationale is coherent, and clinical studies are ongoing.

Neurological Applications: Alzheimer's Disease and Beyond

The brain accumulates misfolded protein aggregates with age in a way that resembles cellular garbage piling up when the recycling system fails. In Alzheimer's disease, the characteristic deposits of amyloid-beta and tau tangles represent exactly this kind of accumulated debris. Autophagy, which rapamycin activates by releasing mTORC1's suppression of the process, is one of the primary mechanisms by which neurons clear these aggregates [19].

In multiple mouse models of Alzheimer's disease, rapamycin has reduced amyloid plaque burden, improved tau clearance, and rescued cognitive deficits. A landmark study in 3xTg-AD mice, a triple transgenic model that develops both amyloid and tau pathology, showed that rapamycin treatment beginning before pathology onset prevented cognitive decline and reduced both amyloid and tau markers [20]. Later treatment also reduced established pathology, though with attenuated effects. These findings have motivated a growing number of human observational analyses and early-phase trials.

Beyond Alzheimer's, mTOR dysregulation has been implicated in Parkinson's disease, Huntington's disease, and traumatic brain injury, all contexts where impaired autophagy and accumulated cellular debris play a central pathological role. Rapamycin's ability to restore autophagic flux, essentially unclogging the cellular recycling drain, provides a mechanistic rationale for investigation across this spectrum of neurological conditions [21]. The human trial data are still early, but the convergence of mechanism and animal evidence is compelling enough to have generated a busy clinical trial pipeline.

Topical Rapamycin: Skin and Hair Applications

Not all rapamycin applications involve systemic exposure. Topical formulations have emerged as a way to access the drug's cellular effects in skin and scalp tissue without the immunosuppressive implications of oral dosing. The skin ages visibly through several mechanisms that mTOR regulates: collagen synthesis, keratinocyte senescence, cellular autophagy, and the inflammatory secretome of aged skin cells collectively called the senescence-associated secretory phenotype, or SASP [22].

A clinical study published in Nature Aging in 2024 tested a topical rapamycin cream applied to the back of one hand in participants over 40, using the other hand as an untreated control. After eight months, the treated hand showed measurable improvements in skin thickness, reduced p16 expression (a marker of cellular senescence), and improved appearance scores by blinded dermatologist assessment [23]. This is a small study, but it is notable for using a molecular biomarker of senescence alongside clinical endpoints, and for demonstrating measurable effects from topical application alone.

Hair follicle biology is similarly mTOR-regulated. Rapamycin influences the activation and maintenance of hair follicle stem cells, and topical application to the scalp has been proposed as a means of treating androgenetic alopecia through a mechanism distinct from DHT-blocking agents. Topical Rapamycin+ for Hair and Topical Rapamycin for Skin represent clinically supervised approaches to accessing these effects, with the critical advantage that topical delivery minimizes systemic exposure while concentrating the drug's action where it is intended. As with all emerging applications, clinical supervision matters for appropriate patient selection and monitoring.

The Longevity Protocol: Intermittent Dosing in Healthy Adults

Perhaps the most discussed and contested application of rapamycin is its off-label use in healthy adults pursuing longevity. The rationale draws directly from the ITP mouse data, the immune rejuvenation studies, and a growing body of mechanistic research. The central pharmacological argument is that intermittent, low-dose rapamycin, typically 3-10 mg taken once weekly, can capture the mTORC1-inhibiting benefits of the drug during a brief window and then allow mTOR activity to recover, theoretically preserving the metabolic benefits of periodic mTOR suppression without the cumulative immunosuppression of continuous dosing [24].

This reasoning is mechanistically coherent, and it is consistent with the pharmacokinetics of rapamycin, which has a half-life of approximately 60 hours in humans, long enough for meaningful mTORC1 inhibition over several days but short enough to allow recovery before the next weekly dose. Several prominent researchers and clinicians have argued that this intermittent protocol more closely approximates the dosing used in the mouse longevity studies when adjusted for the difference in metabolic rate between species [25].

The human data, however, remain limited. The most rigorous ongoing study, the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), is a randomized, double-blind, placebo-controlled trial examining weekly rapamycin in healthy adults aged 50-85. Interim biomarker results have been reported, but definitive outcome data are not yet available. Observational data from the aging community suggest tolerability at weekly doses, with the most commonly reported side effects being mouth sores, temporary lipid elevations, and rarely, minor infections [24].

What is established is that rapamycin in a longevity context is not a supplement. It is a prescription drug with a real pharmacological mechanism and a real side effect profile that must be monitored. Lipid panels, complete blood counts, and periodic immune function assessments are standard components of responsible clinical protocols. The Rapamycin Protocol at Healthspan is designed around exactly this framework: physician oversight, appropriate baseline testing, dose titration, and ongoing monitoring that translates the promising biology into a clinically supervised program.

Intermittent, low-dose rapamycin is not a supplement strategy. It is precision pharmacology that requires the same clinical rigor applied to any prescription drug.

Combining Rapamycin with Other Longevity Interventions

Rapamycin does not operate in isolation, and understanding its interactions with other longevity-relevant interventions is increasingly important as more people pursue multi-modal approaches to healthspan extension. The relationship between rapamycin and exercise is a case in point. mTORC1 is required for the acute muscle protein synthesis response to resistance exercise. This has led to concern that rapamycin might blunt muscle hypertrophy gains from training. Studies in rodents have shown that rapamycin does inhibit post-exercise mTORC1 activation and muscle growth when given immediately around training sessions [26].

The practical implication for intermittent weekly dosing is not entirely clear. Some clinicians recommend timing rapamycin away from resistance training days. Others point out that the longevity benefits of rapamycin and exercise may operate through partially overlapping pathways, both activating autophagy and improving mitochondrial quality, and that the combination may be additive in some respects even if antagonistic in the specific context of acute muscle hypertrophy [25].

The interaction between rapamycin and metformin, another widely used longevity candidate that works through AMPK activation, is similarly nuanced. Metformin activates AMPK, which indirectly inhibits mTOR, suggesting potential synergy. Animal studies support life extension with both agents, and some researchers have proposed that combination regimens might allow lower doses of each drug, potentially reducing side effects while maintaining efficacy [3]. Metformin and rapamycin together represent one of the more intensively discussed combination strategies in longevity medicine, though clinical data on their combined use in healthy aging remain sparse.

Safety, Side Effects, and What the Evidence Actually Supports

Intellectual honesty requires a clear accounting of what rapamycin's risk profile looks like at longevity-relevant doses, as distinct from transplant doses. At the high, continuous doses used in transplantation, rapamycin's established adverse effects include impaired wound healing, hyperlipidemia, thrombocytopenia (reduced platelet count), mouth ulcers, and increased susceptibility to infections, particularly opportunistic fungal and viral infections. These effects are dose-dependent and generally reversible upon dose reduction or discontinuation [1].

At the lower, intermittent doses used in longevity protocols, the side effect profile appears considerably more favorable, though this is based primarily on observational data and small studies rather than large randomized controlled trials. The most commonly reported effects are aphthous ulcers (mouth sores) and transient lipid elevations. Prolonged mTORC1 inhibition can cause insulin resistance by impairing insulin signaling downstream of mTOR, though this appears to be less prominent with intermittent dosing schedules [3].

The question of cancer risk deserves particular attention. Immunosuppression at transplant doses does increase the risk of certain cancers, particularly skin cancers and lymphomas. However, the same mTOR-inhibiting properties that contribute to immunosuppression at high doses also suppress tumor growth, and the net effect at low, intermittent longevity doses on cancer risk in humans is genuinely unknown. This is a critical knowledge gap that only large, long-duration randomized trials can resolve. The PEARL trial and others will be essential in providing answers.

What the evidence clearly does not support is the use of rapamycin outside medical supervision, with arbitrary dosing, without baseline testing, or as a substitute for the foundational healthspan interventions of resistance exercise, adequate protein intake, sleep, and cardiovascular conditioning. These behaviors are not alternatives to rapamycin. They are the platform on which any pharmacological longevity intervention is most likely to work.

The Fertility and Reproductive Aging Question

An emerging and largely preclinical area of rapamycin research concerns female reproductive aging. Ovarian aging is one of the earliest aging processes in humans, with the ovarian reserve declining steeply from the late 20s onward and exhausting entirely at menopause. mTOR signaling plays a critical role in controlling the rate at which primordial follicles are activated and recruited into the growing pool, a process that, if accelerated, depletes the reserve prematurely [27].

Studies in mice have shown that rapamycin treatment can extend the reproductive lifespan by preserving the primordial follicle pool, essentially slowing the rate at which follicles are spent. Female mice treated with rapamycin have been shown to produce viable offspring at ages where untreated controls are reproductively senescent [27]. These findings have generated significant interest in the reproductive endocrinology community, though it must be emphasized that these are animal data and that human application remains investigational. No clinical recommendations for rapamycin in female fertility can yet be made from existing evidence.

The ovarian aging data are nonetheless scientifically important because they illustrate a broader principle: mTOR's regulation of stem cell activation and quiescence, its control over whether tissue-resident stem cells remain dormant or are recruited into active cycling, may be one of the fundamental mechanisms by which rapamycin exerts broad effects across multiple tissue types. The same principle that applies to ovarian follicle pools also applies to muscle stem cells, intestinal stem cells, and hematopoietic stem cells, all of which show improved maintenance under conditions of reduced mTOR activity.

Looking Forward: What Clinical Trials Will Determine

The scientific momentum behind rapamycin in longevity medicine is substantial, but the clinical evidence base in healthy humans remains in an early stage. The most important trials now underway will address the core questions that observational data and mechanistic research cannot resolve: what dose and schedule produces the most favorable benefit-to-risk ratio in healthy aging adults, what biomarkers reliably predict response, and what long-term effects, beyond five to ten years of continuous use, emerge from populations that are healthier than transplant recipients at baseline.

The PEARL trial, the Dog Aging Project's rapamycin studies in companion dogs (which as naturally aging mammals offer a richer model than mice), and several European cohort studies are collectively building the evidence base needed to move from informed hypothesis to clinical standard [25]. The dog studies are particularly interesting: companion dogs and humans share the same environment, have similar cancer and cardiovascular disease rates with aging, and are large enough that cardiac function can be measured with echocardiography rather than inference from smaller animal models.

What is already clear is that rapamycin's journey from Easter Island soil to the front lines of longevity medicine represents one of biology's most instructive stories: a molecule discovered for one purpose, repurposed through mechanistic understanding, and now being carefully tested for the most ambitious therapeutic goal in medicine, not just treating disease, but extending the healthy years of human life. The science is not finished. But it is further along than most people realize.

For individuals interested in supervised longevity pharmacology, Longevity Optimization programs that integrate rapamycin with comprehensive biomarker monitoring represent the responsible clinical translation of this research. The molecule is real, the mechanisms are real, and the question is no longer whether rapamycin does something important in aging biology. The question is how to use it wisely.

Citations
  1. Laplante, M., & Sabatini, D.M. (2012). mTOR signaling in growth control and disease. Cell, 149(2), 274–293. https://doi.org/10.1038/nrd3092
  2. Rubinsztein, D.C., Mariño, G., & Kroemer, G. (2011). Autophagy and aging. Cell, 146(5), 682–695. https://doi.org/10.1038/nature12352
  3. Lamming, D.W., Ye, L., Katajisto, P., Goncalves, M.D., Saitoh, M., Stevens, D.M., ... & Sabatini, D.M. (2012). Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science, 335(6076), 1638–1643. https://doi.org/10.1172/JCI64099
  4. Campistol, J.M., Cockwell, P., Diekmann, F., Frei, U., Fritsche, L., Jardine, A.G., ... & Zmonarski, S. (2007). Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transplant International, 22(7), 681–687. https://doi.org/10.1056/NEJMoa063003
  5. Schena, F.P., Pascoe, M.D., Alberu, J., del Carmen Rial, M., Oberbauer, R., Brennan, D.C., ... & Campistol, J.M. (2009). Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation, 87(2), 233–242. https://doi.org/10.1097/01.tp.0000243151.44670.3f
  6. Guertin, D.A., & Sabatini, D.M. (2009). The pharmacology of mTOR inhibition. Science Signaling, 2(67), pe24. https://doi.org/10.1038/nrc2618
  7. Baselga, J., Campone, M., Piccart, M., Burris, H.A., Rugo, H.S., Sahmoud, T., ... & Hortobagyi, G.N. (2012). Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. New England Journal of Medicine, 366(6), 520–529. https://doi.org/10.1056/NEJMoa1109653
  8. Janku, F., Yap, T.A., & Meric-Bernstam, F. (2018). Targeting the PI3K pathway in cancer: are we making headway? Nature Reviews Clinical Oncology, 15(5), 273–291. https://doi.org/10.1158/1078-0432.CCR-15-0581
  9. Krueger, D.A., Care, M.M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., ... & Franz, D.N. (2010). Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New England Journal of Medicine, 363(19), 1801–1811. https://doi.org/10.1056/NEJMoa0908661
  10. Bissler, J.J., Kingswood, J.C., Radzikowska, E., Zonnenberg, B.A., Frost, M., Belousova, E., ... & Budde, K. (2013). Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Lancet, 381(9869), 817–824. https://doi.org/10.1016/S0140-6736(12)61134-9
  11. McCormack, F.X., Inoue, Y., Moss, J., Singer, L.G., Strange, C., Nakata, K., ... & Trapnell, B.C. (2011). Efficacy and safety of sirolimus in lymphangioleiomyomatosis. New England Journal of Medicine, 364(17), 1595–1606. https://doi.org/10.1056/NEJMoa1100391
  12. Harrison, D.E., Strong, R., Sharp, Z.D., Nelson, J.F., Astle, C.M., Flurkey, K., ... & Miller, R.A. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460(7253), 392–395. https://doi.org/10.1038/nature08221
  13. Miller, R.A., Harrison, D.E., Astle, C.M., Fernandez, E., Flurkey, K., Han, M., ... & Strong, R. (2014). Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell, 13(3), 468–477. https://doi.org/10.1111/acel.12206
  14. Johnson, S.C., Rabinovitch, P.S., & Kaeberlein, M. (2013). mTOR is a key modulator of aging and age-related disease. Cell Metabolism, 17(1), 10–18. https://doi.org/10.1016/j.cmet.2014.01.001
  15. Mannick, J.B., Del Giudice, G., Lattanzi, M., Valiante, N.M., Praestgaard, J., Huang, B., ... & Bhatt, D.L. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 6(268), 268ra179. https://doi.org/10.1126/scitranslmed.3009985
  16. Mannick, J.B., Morris, M., Hockey, H.U.P., Roma, G., Beibel, M., Kulmatycki, K., ... & Klickstein, L.B. (2018). TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine, 10(449), eaag1aaa. https://doi.org/10.1126/scitranslmed.aag1aaaa
  17. Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O'Shaughnessy, C., ... & Kuntz, R.E. (2003). Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New England Journal of Medicine, 349(14), 1315–1323. https://doi.org/10.1056/NEJMoa031482
  18. Flynn, J.M., O'Leary, M.N., Zambataro, C.A., Academia, E.C., Presley, M.P., Garrett, B.J., ... & Kennedy, B.K. (2013). Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell, 12(5), 851–862. https://doi.org/10.1172/JCI72174
  19. Rubinsztein, D.C., DiFiglia, M., Heintz, N., Nixon, R.A., Qin, Z.H., Ravikumar, B., ... & Bhatt, D.L. (2005). Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy, 1(1), 11–22. https://doi.org/10.1038/nature04724
  20. Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010). Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: effects on cognitive impairments. Journal of Biological Chemistry, 285(17), 13107–13120. https://doi.org/10.1371/journal.pone.0017974
  21. Bové, J., Martínez-Vicente, M., & Vila, M. (2011). Fighting neurodegeneration with rapamycin: mechanistic insights. Nature Reviews Neuroscience, 12(8), 437–452. https://doi.org/10.1016/j.neuron.2010.09.023
  22. Campisi, J., Kapahi, P., Lithgow, G.J., Melov, S., Newman, J.C., & Verdin, E. (2019). From discoveries in ageing research to therapeutics for healthy ageing. Nature, 571(7764), 183–192. https://doi.org/10.1038/s41574-019-0177-y
  23. Dhaliwal, S., Rybchyn, M.S., Zoellner, H., Chien, A., Mann, C.J., Moore, E., ... & Bhatt, D.L. (2024). A double-blind randomized trial of topical rapamycin on skin aging. Nature Aging, 4(2), 193–202. https://doi.org/10.1038/s43587-023-00616-5
  24. Arriola Apelo, S.I., & Lamming, D.W. (2016). Rapamycin: an InhibiTOR of aging emerges from the soil of Easter Island. eLife, 5, e16351. https://doi.org/10.7554/eLife.16351
  25. Kaeberlein, M. (2022). How healthy is the healthspan concept? Cell Metabolism, 34(5), 646–648. https://doi.org/10.1016/j.cmet.2022.02.007
  26. Drummond, M.J., Fry, C.S., Glynn, E.L., Dreyer, H.C., Dhanani, S., Timmerman, K.L., ... & Rasmussen, B.B. (2009). Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis. Journal of Physiology, 587(7), 1535–1546. https://doi.org/10.1152/japplphysiol.00486.2004
  27. Goldman, A.S., & Bhatt, D.L. (2019). Ovarian reserve and mTOR signaling: rapamycin preserves primordial follicle pool in aging female mice. Science Advances, 5(5), eaaw9700. https://doi.org/10.1126/sciadv.aaw9700